Neither hydroxychloroquine NOR remdesivir lower inflammation or reduce the degree of respiratory failure in COVID-19 patients, study finds
The NOR-Solidarity, part of the WHO-Solidarity trial, looked at the effects of remdesivir and hydroxychloroquine on hospitalized COVID-19 patients Forty-two patients were randomly assigned to receive remdesivir, 52 patients to receive hydroxychloroquine and 87 patients to receive standard care In all three treatment groups, there were similar decreases in viral loads during the first week of treatment Neither of the drugs reduced the degree respiratory failure or lowered inflammatory markers in COVID-19 patients By Mary Kekatos Acting U.S. Health Editor For Dailymail.Com
Published: 22:00 BST, 12 July 2021 | Updated: 22:01 BST, 12 July 2021
Two COVID-19 treatments do not seem to have any effect in helping patients recover from the disease more quickly, a new study suggests.
Researchers looked at two therapies: remdesivir - which is approved by the U.S. Food and Drug Administration (FDA) to treat Covid and hydroxychloroquine, which is not approved.
They found that neither drug helped decrease the severity of COVID-19 in hospitalized patients nor lowered inflammation no matter what the patient's age was or how long they had had symptoms for.
The team, from Oslo University Hospital, in Norway, says the findings have the group 'questioning the antiviral potential' of the treatments.
A new study found neither remdesivir and hydroxychloroquine reduced the degree respiratory failure or reduced inflammatory makers in
read more from dailymail.....
Tags
fashion
wedding
dress
style
tv mount
Amazon
news
lifestyle
Celebrity News
Kim Kardashian
vichy
neal's yard
aubrey organics
neal's yard remedies
babo botanicals
kiehls store
the body
american auto insurance
auto policy quote
auto quotes online
instant car insurance quote
buy car insurance online
